High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study.
Autor(es): Jackson M. C.; Godwin-Austen R. B.; Whiteley A. M.
Resumo: We report the effects of intravenous gamma-globulin (IVGG) in severe Guillain-Barré syndrome (GBS) in a small open study. Seven patients were given IVGG (0.4 g/kg/day) for 5 consecutive days. At the start of treatment all had progressing limb weakness and none could stand unaided. Within 24 h all but one patient started to improve, without the expected plateau phase, and progress was maintained with a mean time to independent walking of 14 days. One patient started treatment 9 h prior to ventilation for 15 days but was walking independently 31 days after admission. This study provides further evidence that IVGG is a promising therapeutic alternative to plasmapheresis in GBS. The rapidity of the response to IVGG raises the possibility that a single dose regimen might be equally or more effective.
Imprenta: Journal of Neurology, v. 240, n. 1, p. 51-53, 1993
Identificador do objeto digital: 10.1007/BF00838447
Descritores: Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Public health
Data de publicação: 1993
